pbf-1650
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 10, 2018 (NCT03798236)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Adenosine A3 receptorANTAGONIST
ADORA3 antagonist
- Adenosine A1 receptorANTAGONIST
ADORA1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03798236 | Phase 1 | Dec 10, 2018 | Clinica Universidad de Navarra, Paloma Pharmaceuticals, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clinica Universidad de Navarra | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Paloma Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1